Page 1456 - Williams Hematology ( PDFDrive )

1430 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1431

967. Unnikrishnan D, Dutcher JP, Varshneya N, et al: Torsades de pointes in 3 patients with 997. Kolte B, Baer AN, Sait SN, et al: Acute myeloid leukemia in the setting of low dose
leukemia treated with arsenic trioxide. Blood 97:1514, 2001. weekly methotrexate therapy for rheumatoid arthritis. Leuk Lymphoma 42:371, 2001.
968. Zhou J, Meng R, Li X, et al: The effect of arsenic trioxide on QT interval prolongation 998. Bakland G, Nossent H: Acute myelogenous leukemia following etanercept therapy.
during APL therapy. Chin Med J 116:1764, 2003. Rheumatology (Oxford) 42:900, 2003.
969. Fenaux P, Chastang C, Chevret S, et al: A randomized comparison of all-trans retinoic 999. Noronha V, Berliner N, Ballen KK, et al: Treatment-related myelodysplasia/AML
acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role in a patient with a history of breast cancer and an oligodendroglioma treated with
of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The Euro- temozolomide: Case study and review of the literature. Neuro Oncol 8:280, 2006.
pean APL Group. Blood 94:1192, 1999. 1000. Aktan M, Tanakol R, Nalcaci M, Dincol G: Leukemia in a patient treated with growth
970. Ades L, Guerci A, Raffoux E, et al: Very long-term outcome of acute promyelocytic hormone. Endocr J 47:471, 2000.
leukemia after treatment with all-trans retinoic acid and chemotherapy: The European 1001. Freedman MH, Bonilla MA, Fier C, et al: Myelodysplasia syndrome and acute mye-
APL Group experience. Blood 115:1690, 2010. loid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood
971. Thirugnanam R, George B, Chendamarai E, et al: Comparison of clinical outcomes 96:429, 2000.
of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide 1002. Andersen MK, Pedersen-Bjergaard J: Therapy-related MDS and AML in acute promy-
and consolidated with either an autologous stem clel transplant or an arsenic triox- elocytic leukemia. Blood 100:1928, 2002.
ide-based regimen. Biol Blood Marrow Transplant 15:1479, 2009. 1003. Barnard DR, Lange B, Alonzo TA, et al: Acute myeloid leukemia and myelodysplas-
972. de Bottom S, Fawaz A, Chevret S, et al: Autologous and allogeneic stem-cell trans- tic syndrome in children treated for cancer: Comparison with primary presentation.
plantation as salvage treatment of acute promyelocytic leukemia initially treated with Blood 100:427, 2002.
all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic 1004. Smith RE, Bryant J, DeCillis A, et al: Acute myeloid leukemia and myelodysplastic
leukemia groups. J Clin Oncol 23:120, 2005. syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast
973. Aribi A, Kantarjian HM, Estey EH, et al: Combination therapy with arsenic trioxide, cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin
all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic Oncol 21:1195, 2003.
leukemia. Cancer 109:1355, 2007. 1005. Gershkevitsh E, Rosenberg I, Dearnaley DP, Trott KR: Bone marrow doses and leuke-
974. Lo-Coco F, Romano A, Mengarelli A, et al: Allogeneic stem cell transplantation for mia risk in radiotherapy of prostate cancer. Radiother Oncol 53:189, 1999.
advanced acute promyelocytic leukemia: Results in patients treated in second molec- 1006. Armitage JO, Carbone PP, Connors JM, et al: Treatment-related myelodysplasia and
ular remission or with molecularly persistent disease. Leukemia 17:1930, 2003. acute leukemia in non-Hodgkin’s lymphoma. J Clin Oncol 21:897, 2003.
975. Nabhan C, Mehta J, Tallman MS: The role of bone marrow transplantation in acute 1007. Lambertenghi Deliliers G, Annaloro C, Pozzoli E, et al: Cytogenetic and myelodys-
promyelocytic leukemia. Bone Marrow Transplant 28:219, 2001. plastic alterations after autologous hemopoietic stem cell transplantation. Leuk Res
976. Colvic N, Bogdanovic A, Miljic P, et al: Central nervous system relapse in acute pro- 23:291, 1999.
myelocytic leukemia. Am J Hematol 71:60, 2002. 1008. Legare RD, Gribben JG, Maragh M, et al: Prediction of therapy-related acute myelog-
977. Sanz MA, Larrea L, Sanz G, et al: Cutaneous promyelocytic sarcoma at sites of vascu- enous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone
lar access and marrow aspiration. A characteristic localization of chloromas in acute marrow transplant (ABMT) for lymphoma. Am J Hematol 56:45, 1997.
promyelocytic leukemia? Haematologica 85:758, 2000. 1009. Micallef IN, Lillington DM, Apostolidis J, et al: Therapy-related myelodysplasia and
978. Latagliata R, Carmosino I, Breccia M, et al: Late relapses in acute promyelocytic leu- secondary acute myelogenous leukemia after high-dose therapy with autologous
kaemia. Acta Haematol 117:106, 2007. hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol
979. Esteve J, Escoda L, Martín G, et al: Outcome of patients with acute promyelocytic 18:847, 2000.
leukemia failing to front-line treatment with all-trans retinoic acid and anthracy- 1010. Lillington DM, Micallef IN, Carpenter E, et al: Detection of chromosome abnormal-
cline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an ities pre-high-dose treatment in patients developing therapy-related myelodysplasia
early intervention. Leukemia 21:446, 2007. and secondary acute myelogenous leukemia after treatment for non-Hodgkin’s lym-
980. Latagliata R, Petti MC, Fenu S, et al: Therapy-related myelodysplastic syndrome-acute phoma. J Clin Oncol 19:2472, 2001.
myelogenous leukemia in patients treated for acute promyelocytic leukemia: An 1011. Estey EH: Treatment of acute myelogenous leukemia and myelodys-plastic syn-
emerging problem. Blood 99:822, 2002. dromes. Semin Hematol 32:132, 1995.
981. Lobe I, Rigal-Huguet F, Vekhoff A, et al: Myelodysplastic syndrome after acute promy- 1012. Witherspoon RP, Deeg HJ, Storer B, et al: Hematopoietic stem-cell transplantation for
elocytic leukemia: The European APL group. Leukemia 17:1600, 2003. treatment-related leukemia or myelodysplasia. J Clin Oncol 19:2134, 2001.
982. Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E: Therapy-related myelodys- 1013. Costa LJ, Rodriguez V, Porrata LF, et al: Autologous HSC transplant in t-MDS/AML
plastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic using cells harvested prior to the development of the secondary malignancy. Bone
leukemia (APL). Leukemia 16:1888, 2002. Marrow Transplant 42:497, 2008.
983. Jantunen E, Heinonen K, Mahlamäki E, et al: Secondary acute promyelocytic leuke- 1014. Anderson JE, Gooley TA, Schoch G, et al: Stem cell transplantation for secondary
mia: An increasingly common entity. Leuk Lymphoma 48:190, 2007. acute myeloid leukemia: Evaluation of transplantation as initial therapy or following
984. Yoo SJ, Park CJ, Jang S, et al: Inferior prognostic outcome in acute promyelocytic leu- induction chemotherapy. Blood 89:2578, 1997.
kemia with alterations of FLT3 gene. Leuk Lymphoma 47:1788, 2006. 1015. Rowe JM: Therapy of secondary leukemia. Leukemia 16:748, 2002.
985. Gallagher RE, Moser BK, Racevskis J, et al: Treatment-influenced associations of 1016. Rosenfield C, Kantarjian H: Is myelodysplastic related acute myelogenous leukemia
PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities a distinct entity from de novo acute myelogenous leukemia? Potential for targeted
in relapsed acute promyelocytic leukemia. Blood 120: 2098, 2012. therapies. Leuk Lymphoma 41:493, 2001.
986. Lu DP, Qiui JY, Jiang B, et al: Tetra-arsenic tetra-sulfide for the treatment of acute 1017. Viniou NA, Vassilakopoulos TP, Giakoumi X, et al: Ida-FLAG plus imatinib mesy-
promyelocytic leukemia: A pilot report. Blood 99:2136, 2002. late-induced remission with chemoresistant Ph1+ acute myeloid leukemia. Eur J Hae-
987. Takeuchi M, Yano T, Omoto E, et al: Relapsed acute promyelocytic leukemia previ- matol 72:58, 2004.
ously treated with all-trans retinoic acid: Clinical experience with a new synthetic 1018. Brincker H: Estimate of overall treatment results in acute nonlymphocytic leukemia
retinoid, Am-80. Leuk Lymphoma 31:441, 1998. based on age-specific rates of incidence and complete remission. Cancer Treat Rep
988. Bally C, FadallahJ, Leverger G, et al: Outcome of acute promyelocytic leukemia (APL) 69:5, 1985.
in children and adolescents: An analysis in two consecutive trials of the European 1019. Büchner T, Berdel WE, Haferlach C, et al: Age-related risk profile and chemotherapy
APL group. J Clin Oncol 30:1641, 2012. dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leu-
989. Smith MA, McCaffrey RP, Karp JE: The secondary leukemias: Challenges and research kemia Cooperative Group. J Clin Oncol 27:61, 2009.
directions. J Natl Cancer Inst 88:407, 1996. 1020. Kuendgen A, Germing U: Emerging treatment strategies for acute myeloid leukemia
990. Smith MA, Rubinstein L, Anderson JR, et al: Secondary leukemia or myelodysplastic (AML) in the elderly. Cancer Treat Rev 35:97, 2009.
syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17:569, 1999. 1021. Dombret H, Raffoux E, Gardin C: Acute myeloid leukemia in the elderly. Semin Oncol
991. Ng A, Taylor GM, Eden OB: Treatment-related leukaemia: A clinical and scientific 35:430, 2008.
challenge. Cancer Treat Rev 26:377, 2000. 1022. Ferrara F, Pinto A: Acute myeloid leukemia in the elderly: Current therapeutic results
992. Super HJ, McCabe NR, Thirman MJ, et al: Rearrangements of the MLL gene in ther- and perspectives for clinical research. Rev Recent Clin Trials 2:33, 2007.
apy-related acute myeloid leukemia in patients previously treated with agents target- 1023. Pinto A, Zulian GB, Archimbaud E: Acute myelogenous leukaemia. Crit Rev Oncol
ing DNA-topoisomerase 11. Blood 82:3705, 1993. Hematol 27:161, 1998.
993. Dissing M, Le Beau MM, Pedersen-Bjergaard J: Inversion of chromosome 16 and 1024. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: Assess-
uncommon rearrangements of the CBFB and MYHI1 genes in therapy-related acute ment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic sub-
myeloid leukemia: Rare events related to DNA-topoisomerase II inhibitors? J Clin groups with remarkably distinct responses to standard chemotherapy. A Southwest
Oncol 16:1890, 1998. Oncology Group study. Blood 89:3323, 1997.
994. Gondek LP, Tiu R, O’Keefe CL, et al: Chromosomal lesions and uniparental disomy detected 1025. Bacher U, Kern W, Schnittger S, et al: Population-based age-specific incidences of
by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534, 2008. cytogenetic subgroups of acute myeloid leukemia. Haematologica 90:1502, 2005.
995. Seedhouse C, Russell N: Advances in the understanding of susceptibility to treat- 1026. Ballester O, Moscinski LC, Morris D, Balducci L: Acute myelogenous leukemia in the
ment-related acute myeloid leukaemia. Br J Haematol 137:513, 2007. elderly. J Am Geriatr Soc 40:277, 1992.
996. Pogliani EM, Pioltelli P, Russini F, et al: Acute leukemia following cisplatin for ovarian 1027. Klepin HD, Rao AV, Pardee TS: Acute myeloid leukemia and myelodysplastic syn-
cancer [letter]. Haematologica 72:184, 1987. dromes in older adults. J Clin Oncol 23:2541, 2014.

Kaushansky_chapter 88_p1373-1436.indd 1431 9/21/15 11:02 AM